(-)-(2R,4)-dimethyl-pentanoic acid tert-butyl ester | 125427-94-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (-)-(2R,4)-dimethyl-pentanoic acid tert-butyl ester
• 英文别名: (R)-tert-butyl 2,4-dimethylpentanoate；tert-butyl (2R)-2,4-dimethylpentanoate
• CAS: 125427-94-3
• 化学式: C₁₁H₂₂O₂
• 分子量: 186.294
• InChiKey: PJCVELDASPSMIA-SECBINFHSA-N

物化性质

• 沸点：
  183.5±8.0 °C(Predicted)
• 密度：
  0.868±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (-)-(2R,4)-dimethyl-pentanoic acid tert-butyl ester 在 咪唑 、 lithium aluminium tetrahydride 、 碘 、 三苯基膦 作用下， 以 乙醚 为溶剂， 生成 (R)-1-bromo-2,4-dimethylpentane
  参考文献：
  名称：

  METHOD FOR PREPARING VITTATALACTONE

  摘要：

  本发明涉及条纹黄瓜甲（Acalymma vittatum）聚集信息素vittatalactone的化学合成。

  公开号：

  US20110282075A1
• 作为产物：
  描述：

  (-)-(2S)-trifluoromethanesulfonyloxy-4-methyl-pentanoic acid tert-butyl ester 、 甲基氯化镁 在 zinc(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以81%的产率得到(-)-(2R,4)-dimethyl-pentanoic acid tert-butyl ester
  参考文献：
  名称：

  Zinc‐Catalyzed Enantiospecific sp³–sp³ Cross‐Coupling of α‐Hydroxy Ester Triflates with Grignard Reagents

  摘要：

  DOI：

  10.1002/anie.200800733

文献信息

• NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150023989A1

  公开（公告）日：2015-01-22

  The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

  本申请涉及针对FGFR2靶点的新抗体药物结合物（ADCs），所述ADCs的药物代谢产物，生产所述ADCs的方法，利用所述ADCs治疗和/或预防疾病以及利用所述ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病如癌症。这种治疗可以作为单药疗法进行，也可以与其他药物或额外的治疗措施结合使用。
• Novel Binder-Drug Conjugates (ADCs) and Use of Same
  申请人：Lerchen Hans-Georg

  公开号：US20140127240A1

  公开（公告）日：2014-05-08

  The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

  本专利申请涉及针对表皮生长因子受体（EGFR，基因ID 1956）的新型结合物-药物共轭物（ADCs）N，N-二烷基月桂酰基蛋白酶抑制剂，这些ADCs的有效代谢物，生产这些ADCs的方法，利用这些ADCs治疗和/或预防疾病以及利用这些ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病，如癌症。这种治疗可以作为单药疗法或与其他药物或其他治疗措施联合使用。
• Enantioselective Total Synthesis of the Unnatural and the Natural Stereoisomers of Vittatalactone
  作者：Yvonne Schmidt、Konrad Lehr、Ulrich Breuninger、Gabriel Brand、Tomislav Reiss、Bernhard Breit

  DOI：10.1021/jo100383u

  日期：2010.7.2

  of the cucumber beetle. In this context, we developed the asymmetric total synthesis of the aggregation pheromone of A. vittatum, Vittatalactone, to determine its absolute configuration and to further examine the pheromone response in field studies. The synthesis features an enzyme-catalyzed approach toward the deoxypropionate structural motif. A preformed organocopper reagent could then be coupled in

  条纹黄瓜甲虫Acalymma vittatum是造成北美葫芦作物严重受损的原因。为了制定对环境无害的植物保护策略，最近的研究集中在鉴定黄瓜甲虫的性信息素。在这种情况下，我们开发了A. vittatum的聚集信息素的不对称全合成，Vittatalactone，以确定其绝对构型，并在野外研究中进一步检查了信息素的反应。合成的特征是通过酶催化的方法实现脱氧丙酸酯的结构基序。预成型有机铜试剂然后可以在被耦合的对映选择性ö -DPPB定向烯丙基取代与官能ö-DPPB-酯。通过这种有效的转化，可以在高度收敛的合成过程中获得维他他内酯。
• NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150030618A1

  公开（公告）日：2015-01-29

  The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及针对C4.4a靶点的新型N，N-二烷基月桂酰基链霉素结合物（ADCs），这些ADCs的活性代谢物，制备这些ADCs的方法，使用这些ADCs治疗和/或预防疾病，以及使用这些ADCs制造治疗和/或预防疾病的药物，特别是治疗和/或预防过度增殖和/或血管生成性疾病，例如癌症。这样的治疗可以作为单一疗法或与其他药物或进一步治疗措施结合使用。
• New binder-drug conjugates (ADCs) and use thereof
  申请人：Bayer Pharma AG

  公开号：US20130095123A1

  公开（公告）日：2013-04-18

  The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新的结合剂-药物共轭物（ADCs），其为N，N-二烷基月桂酰基蛋白酶抑制剂，针对C4.4a靶标，以及这些ADCs的活性代谢物，制备这些ADCs的方法，使用这些ADCs治疗和/或预防疾病，以及使用这些ADCs制备治疗和/或预防疾病的药物，更具体地说是治疗和/或预防增生和/或血管生成性疾病，例如癌症。这种治疗可以作为单一疗法，也可以与其他药物或进一步的治疗措施结合使用。